1998至2015年马德里社区无细胞百日咳疫苗效力及百日咳发病率演变
该研究分析马德里社区1998至2015年法定报告系统3855例百日咳病例,采用筛查法评估不同无细胞百日咳疫苗接种程序的疫苗效力。结果显示近年发病率上升,2013-2015年发病率比5.99,<1月龄婴儿发病率比32.41;疫苗效力随剂次增加而升高,随随访时间延长而下降。
要点
- 1998至2015年共报告3855例百日咳,流行间期每3-4年出现一次。
- 2013-2015年发病率比较期发病率为参考期的5.99倍,<1月龄婴儿为32.41倍。
- 末剂接种≤6月龄者随访1年疫苗效力89.9%,随访11年降至85.5%。
核心结论
- 百日咳杆菌在人群中持续循环,近年出现流行高峰和发病率上升。
- 疫苗效力随接种剂次增加而升高,随随访时间延长而下降。
- 需监测本策略及其他疫苗接种策略的效果以控制疾病。
研究设计与样本
- 分析1998至2015年马德里社区法定疾病报告系统通报的百日咳病例。
- 设5个比较期:1998-2001(参考)、2002-2005、2006-2009、2010-2012、2013-2015。
- 采用泊松回归分析流行间期发病率比,采用筛查法计算疫苗效力,疫苗状态数据来自疫苗登记处。
主要发现
- 共报告3855例百日咳,流行间期每3-4年出现一次。
- 2013-2015期发病率比较期上升,发病率比5.99(p<0.05),<1月龄婴儿发病率比32.41(p<0.05)。
- 89%的病例有疫苗接种数据。
- 末剂接种≤6月龄者随访1年疫苗效力89.9%(95%CI:87.3-92.0),随访11年85.5%(95%CI:82.4-88.1)。
- 末剂接种18月龄者疫苗效力从98.8%(95%CI:98.3-99.1)降至85.1%(95%CI:81.9-87.7);末剂接种4岁者从99.6%(95%CI:99.3-99.7)降至79.3%(95%CI:74.6-83.1)。
关键数值与推荐
- 末剂接种≤6月龄:随访1年疫苗效力89.9%(95%CI:87.3-92.0),随访11年85.5%(95%CI:82.4-88.1)。
- 末剂接种18月龄:疫苗效力从98.8%(95%CI:98.3-99.1)降至85.1%(95%CI:81.9-87.7)。
- 末剂接种4岁:疫苗效力从99.6%(95%CI:99.3-99.7)降至79.3%(95%CI:74.6-83.1)。
- 2013-2015期发病率比5.99(p<0.05),<1月龄婴儿发病率比32.41(p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pertussis is a communicable disease that primarily affects infants. Vaccination has led to an important reduction in the incidence of the disease, however, resurgence of the disease has been observed. This study aimed to analyze the incidence of pertussis and assess the vaccination effectiveness (VE) of different schedules of acellular pertussis vaccination in the community of Madrid. METHODS: Pertussis cases notified to the Mandatory Disease Reporting System from 1998 to 2015 were analyzed. Five comparison periods were created: 1998-2001 (reference), 2002-2005, 2006-2009, 2010-2012 and 2013-2015. The incidence ratio (IR) between inter-epidemic periods was analyzed using a Poisson regression. VE was calculated using the screening method. Vaccine status data were collected from the vaccine registry. RESULTS: In total, 3855 cases were notified. Inter-epidemic periods were observed every 3-4 years. The incidence increased (IR: 5.99, p < 0.05) in the 2013-2015 period, particularly among infants younger than 1 month (IR: 32.41, p < 0.05). Vaccination data were available in 89% of cases. For those receiving the last dose at ≤6-month VE was 89.9% (95% confidence interval (CI): 87.3-92.0) after one year of follow-up, and 85.5% (95% CI: 82.4-88.1) after 11 years of follow-up. For those receiving the last dose at 18-months VE decreased from 98.8% (95% CI: 98.3-99.1) to 85.1% (95% CI: 81.9-87.7) in the same period, and for those receiving the last dose at 4-year VE decreased from 99.6% (95% CI: 99.3-99.7) to 79.3% (95% CI: 74.6-83.1). CONCLUSIONS: B. pertussis is circulating in our population, as shown by the epidemic peaks and increased incidence of pertussis in recent years. VE increased with the number of doses and decreased with the follow-up period. The effect of this and other vaccination strategies must be monitored to control the disease.
引用
- Latasa P, García-Comas L, Gil de Miguel A, et al. Effectiveness of acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to 2015. Vaccine. 2018. PMID: 29439872. doi:10.1016/j.vaccine.2018.01.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。